Independent re/insurance broker BMS Group has introduced BMS Bacchus, a stock throughput insurance solution designed to ...

AbbVie Inc.'s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., analysts said.

This was partly offset by a 1% rise in the company’s revenue from $46 billion to $47 billion over the same period; and a 4.1% ...

Specialist Risk Group has acquired Essex-based One Claim Limited. The business, which provides broker partners and their ...

Highlights,NXP Semiconductors launches Ultra-Wideband (UWB) Battery Management System (BMS) for electric vehicles, reducing ...

report_id=5373 The global Battery Management System (BMS) market emerges as a catalyst for change, poised to reach an impressive USD 14,422 million by 2026, according to a comprehensive study by ...

The acquisition gave BMS control of Karuna’s lead asset, KarXT (xanomeline-trospium), an antipsychotic with a novel mechanism ...

Bristol Myers Squibb stock rocketed Monday after AbbVie's experimental schizophrenia treatment failed in a pair of midstage studies.

The Chicago-based firm earlier announced that its two Phase II EMPOWER trials investigating emraclidine as a once-daily, oral ...

AbbVie reports disappointing mid-stage data for its schizophrenia drug. Jason Snipe of Odyssey Capital still likes AbbVie ...

Independent specialist insurance broker BMS Group has launched BMS Bacchus, a stock throughput solution designed to protect ...

The shocking failure of AbbVie’s emraclidine has investors questioning the Big Pharma’s long-term neuroscience strategy, ...